title: Cashing in on royalties. Sloan-Kettering reaps 142 million dollars in deal.
authors.forename: Cinda
authors.initials: C
authors.lastname: Becker
mesh_terms: D000047:Academies and Institutes / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics*; D002173:Cancer Care Facilities / Q000191:economics*; D002202:Capital Financing / Q000379:methods*; D003132:Commerce; D006784:Hospitals, Teaching / Q000191:economics; D006801:Humans; D018973:Intellectual Property; D009519:New York City; D012106:Research / Q000191:economics
chemical_list: D000970:Antineoplastic Agents